
Opinion|Videos|November 22, 2024
MOA and Improved Outcomes: Gaps in Measuring Real-World Results
Key Takeaways
Sumit Sharma, MD, FASRS ponders to the panel the root cause of improved outcomes with newer agents. The panel then highlights current gaps in measuring visual improvements beyond tools such as the OCT, emphasizing the need for patient-centered treatment plans.
Advertisement
Episodes in this series

Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
2
PainReform launches development plan for OcuRing-K, readies phase 2 trial
3
Avisi Technologies treats first patient in SAPPHIRE trial for glaucoma
4
FDA approves Amneal Pharmaceuticals' cyclosporine ophthalmic emulsion 0.05%
5















































.png)


